166 related articles for article (PubMed ID: 21181022)
1. [Evaluation of APRI score in liver disease following the introduction of antiretroviral therapy in HIV and HCV coinfected versus HIV monoinfected patients].
Antonello VS; Tovo CV; Kliemann DA; Santos BR; Zaltron VF
Rev Soc Bras Med Trop; 2010; 43(6):678-81. PubMed ID: 21181022
[TBL] [Abstract][Full Text] [Related]
2. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker.
Al-Mohri H; Murphy T; Lu Y; Lalonde RG; Klein MB
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):463-9. PubMed ID: 17211282
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection.
Price JC; Seaberg EC; Phair JP; Witt MD; Koletar SL; Thio CL
J Acquir Immune Defic Syndr; 2016 Jul; 72(3):319-23. PubMed ID: 26945179
[TBL] [Abstract][Full Text] [Related]
4. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients.
Cooper C; Rollet-Kurhajec KC; Young J; Vasquez C; Tyndall M; Gill J; Pick N; Walmsley S; Klein MB;
HIV Med; 2015 Jan; 16(1):24-31. PubMed ID: 24837567
[TBL] [Abstract][Full Text] [Related]
5. Biochemical non-invasive assessment of liver fibrosis cannot replace biopsy in HIV-HCV coinfected patients.
Kliemann DA; Wolff FH; Tovo CV; Alencastro PR; Ikeda ML; Brandão AB; Barcellos N; Fuchs SC
Ann Hepatol; 2016; 15(1):27-32. PubMed ID: 26626637
[TBL] [Abstract][Full Text] [Related]
6. Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.
Rollet-Kurhajec KC; Moodie EE; Walmsley S; Cooper C; Pick N; Klein MB;
PLoS One; 2015; 10(6):e0129868. PubMed ID: 26090666
[TBL] [Abstract][Full Text] [Related]
7. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?
Verma S; Wang CH; Govindarajan S; Kanel G; Squires K; Bonacini M
Clin Infect Dis; 2006 Jan; 42(2):262-70. PubMed ID: 16355339
[TBL] [Abstract][Full Text] [Related]
8. Impact of HAART on liver histology of HIV/HCV coinfected patients.
De Bona A; Sitia G; Uberti-Foppa C; Galli L; Ciuffreda D; Gallotta G; Paties C; Lazzarin A
J Biol Regul Homeost Agents; 2003; 17(2):195-7. PubMed ID: 14518723
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection.
Mendeni M; Focà E; Gotti D; Ladisa N; Angarano G; Albini L; Castelnuovo F; Carosi G; Quiros-Roldan E; Torti C
Clin Infect Dis; 2011 May; 52(9):1164-73. PubMed ID: 21467023
[TBL] [Abstract][Full Text] [Related]
10. Transient liver injury associated with the early recovery of HCV-specific T-cell responses and HCV rebound in HIV-1/HCV coinfected patients undergoing highly active antiretroviral therapy.
Kang F; Chen W; Zhang X; Nie W; Fu J; Xu X; Zhao P; Zhang X; Li W; Wang FS; Zhang Z; Zhao M
J Acquir Immune Defic Syndr; 2013 Feb; 62(2):135-42. PubMed ID: 23075912
[TBL] [Abstract][Full Text] [Related]
11. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease.
Nunes D; Fleming C; Offner G; O'Brien M; Tumilty S; Fix O; Heeren T; Koziel M; Graham C; Craven DE; Stuver S; Horsburgh CR
J Acquir Immune Defic Syndr; 2005 Dec; 40(5):538-44. PubMed ID: 16284529
[TBL] [Abstract][Full Text] [Related]
12. Correlation of transient elastography with APRI and FIB-4 in a cohort of patients with congenital bleeding disorders and HCV or HIV/HCV coinfection.
Vidovic N; Lochowsky RS; Goldmann G; Rockstroh J; Wasmuth JC; Spengler U; Sauerbruch T; Lammert F; Oldenburg J; Grünhage F
Haemophilia; 2010 Sep; 16(5):778-85. PubMed ID: 20331759
[TBL] [Abstract][Full Text] [Related]
13. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
Fuster D; Planas R; Muga R; Ballesteros AL; Santos J; Tor J; Sirera G; Guardiola H; Salas A; Cabré E; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Tural C
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1293-7. PubMed ID: 15650421
[TBL] [Abstract][Full Text] [Related]
14. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.
Moodie EE; Pant Pai N; Klein MB
PLoS One; 2009; 4(2):e4517. PubMed ID: 19223976
[TBL] [Abstract][Full Text] [Related]
15. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.
Bräu N; Salvatore M; Ríos-Bedoya CF; Fernández-Carbia A; Paronetto F; Rodríguez-Orengo JF; Rodríguez-Torres M
J Hepatol; 2006 Jan; 44(1):47-55. PubMed ID: 16182404
[TBL] [Abstract][Full Text] [Related]
16. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients.
Mohsen AH; Easterbrook PJ; Taylor C; Portmann B; Kulasegaram R; Murad S; Wiselka M; Norris S
Gut; 2003 Jul; 52(7):1035-40. PubMed ID: 12801963
[TBL] [Abstract][Full Text] [Related]
17. Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons.
Brunet L; Moodie EEM; Young J; Cox J; Hull M; Cooper C; Walmsley S; Martel-Laferrière V; Rachlis A; Klein MB; ; Cohen J; Conway B; Cooper C; Côté P; Cox J; Gill J; Haider S; Sadr A; Johnston L; Hull M; Montaner J; Moodie E; Pick N; Rachlis A; Rouleau D; Sandre R; Tyndall JM; Vachon ML; Sanche S; Skinner S; Wong D
Clin Infect Dis; 2016 Jan; 62(2):242-249. PubMed ID: 26400998
[TBL] [Abstract][Full Text] [Related]
18. Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.
Casado JL; Mena A; Bañón S; Castro A; Quereda C; Moreno A; Pedreira J; Moreno S
HIV Med; 2016 Jan; 17(1):62-7. PubMed ID: 26122981
[TBL] [Abstract][Full Text] [Related]
19. Liver fibrosis progression in HIV/hepatitis C virus coinfected patients with normal aminotransferases levels.
Pace FH; Ferreira LE; Silva AE; Ferraz ML
Rev Soc Bras Med Trop; 2012; 45(4):444-7. PubMed ID: 22930041
[TBL] [Abstract][Full Text] [Related]
20. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
